Developer docs
API playgroundTry for free, no card

Search company profiles

Mannin Research

Full company profile

uuid00036ob

Namestring
Mannin Research
Legal namestring
Mannin Research Inc.
Websiteurl
mannin.ca
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Mannin Research Inc. is a privately-held Canadian biotechnology company founded in 2016 and headquartered at 80 Atlantic Avenue, Toronto, Ontario. The company is focused on developing and commercializing novel therapeutics for ophthalmic diseases, with its first clinical indication being glaucoma. Mannin pursues a first-in-class drug development strategy centered on therapeutics that engage the Ang-Tie2 signaling pathway—a mechanism implicated in vascular endothelial function and ocular homeostasis.

The company's product portfolio consists of novel drug candidates designed to modulate the Ang-Tie2 mechanism of action to address unmet medical needs in ophthalmology, beginning with glaucoma. Mannin is operating at a very early stage with a team of 1-10 employees, no commercial products, no disclosed partnerships, and no named customers or licensing relationships in the available data. The company's value proposition rests on differentiated biology—the first-in-class positioning of Ang-Tie2 engagement for ocular disease—and its prioritized focus on glaucoma, a large indication with significant unmet need despite existing therapeutic options.

Mannin Research operates as a pre-commercial biotech. No pricing model, distribution channels, marketing channels, or revenue mechanics are in place, and no commercial milestones have been disclosed. The company has raised approximately $3.38 million in funding from Q BioMed as lead investor in November 2022. Future commercialization will likely depend on out-licensing, strategic partnerships, or direct commercialization of approved ophthalmic drugs following clinical and regulatory milestones, none of which have been publicly disclosed to date.

Short descriptiontext

Mannin Research Inc. is a privately-held, Toronto-based biotechnology company developing first-in-class therapeutics targeting the Ang-Tie2 mechanism of action to treat ophthalmic diseases, with its lead indication being glaucoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic therapeutics, biopharmaceutical development, glaucoma treatment, first-in-class drugs, novel drug discovery
Industry3 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mannin Research develops and commercializes novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's first indication is glaucoma, treated with novel, first-in-class drugs. The company is a pre-commercial biotechnology company focused on the discovery and development of these innovative new drugs to address unmet needs in ophthalmology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mannin Research is a biotechnology company developing a single portfolio of novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's lead indication is glaucoma, with drugs classified as first-in-class treatments. Mannin is focused on both developing and commercializing these innovative new drugs to address patient needs in ophthalmology.

Product and service1 record
1Novel Ang-Tie2 Therapeutics (Glaucoma Program)
CategoryOphthalmic Therapeutics
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mannin Research

Ophthalmic Biopharmaceuticalsmannin.ca

Mannin Research Inc. is a privately-held, Toronto-based biotechnology company developing first-in-class therapeutics targeting the Ang-Tie2 mechanism of action to treat ophthalmic diseases, with its lead indication being glaucoma.

What Mannin Research does

Mannin Research Inc. is a privately-held Canadian biotechnology company founded in 2016 and headquartered at 80 Atlantic Avenue, Toronto, Ontario. The company is focused on developing and commercializing novel therapeutics for ophthalmic diseases, with its first clinical indication being glaucoma. Mannin pursues a first-in-class drug development strategy centered on therapeutics that engage the Ang-Tie2 signaling pathway—a mechanism implicated in vascular endothelial function and ocular homeostasis.

The company's product portfolio consists of novel drug candidates designed to modulate the Ang-Tie2 mechanism of action to address unmet medical needs in ophthalmology, beginning with glaucoma. Mannin is operating at a very early stage with a team of 1-10 employees, no commercial products, no disclosed partnerships, and no named customers or licensing relationships in the available data. The company's value proposition rests on differentiated biology—the first-in-class positioning of Ang-Tie2 engagement for ocular disease—and its prioritized focus on glaucoma, a large indication with significant unmet need despite existing therapeutic options.

Mannin Research operates as a pre-commercial biotech. No pricing model, distribution channels, marketing channels, or revenue mechanics are in place, and no commercial milestones have been disclosed. The company has raised approximately $3.38 million in funding from Q BioMed as lead investor in November 2022. Future commercialization will likely depend on out-licensing, strategic partnerships, or direct commercialization of approved ophthalmic drugs following clinical and regulatory milestones, none of which have been publicly disclosed to date.

Mannin Research firmographics

Firmographics
Name
Mannin Research
Legal name
Mannin Research Inc.
Website
https://mannin.ca
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Mannin Research Inc. is a privately-held, Toronto-based biotechnology company developing first-in-class therapeutics targeting the Ang-Tie2 mechanism of action to treat ophthalmic diseases, with its lead indication being glaucoma.
Ownership category
akta.pro rank

Mannin Research industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Ophthalmic therapeutics
  • Biopharmaceutical development
  • Glaucoma treatment
  • First-in-class drugs
  • Novel drug discovery

Where Mannin Research is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Mannin Research business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Mannin Research product offering

Product offering

Core offering

Mannin Research develops and commercializes novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's first indication is glaucoma, treated with novel, first-in-class drugs. The company is a pre-commercial biotechnology company focused on the discovery and development of these innovative new drugs to address unmet needs in ophthalmology.

Product overview

Mannin Research is a biotechnology company developing a single portfolio of novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's lead indication is glaucoma, with drugs classified as first-in-class treatments. Mannin is focused on both developing and commercializing these innovative new drugs to address patient needs in ophthalmology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel Ang-Tie2 Therapeutics (Glaucoma Program)

Companies that use Mannin Research

Customer profile

Segments1 record

Ideal customer profiles1 record

Mannin Research technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mannin Research partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Mannin Research competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Mannin Research social profiles

Digital presence

Mannin Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mannin Research leadership team

Management profile

Number of profiles

Mannin Research funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mannin Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mannin Research

What does Mannin Research do?

Mannin Research develops and commercializes novel therapeutics targeting the Ang-Tie2 mechanism of action for ophthalmic diseases. The company's first indication is glaucoma, treated with novel, first-in-class drugs. The company is a pre-commercial biotechnology company focused on the discovery and development of these innovative new drugs to address unmet needs in ophthalmology.

Is Mannin Research a public or private company?

Mannin Research is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mannin Research founded?

Mannin Research was founded in 2016. It employs 1 to 10 people.

Where is Mannin Research based?

Mannin Research is headquartered in Toronto, Canada, in the North America region.

Does Mannin Research have an API?

No public API is recorded for Mannin Research.

What industry is Mannin Research in?

Mannin Research's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.Q BioMed Inc. has converted its long-term royalty agreement into a 15% equity stake in Mannin Research Inc., a private Canadian biotechnology company, while retaining a $20 million royalty on future net sales. This transaction allows Q BioMed to recognize approximately CAD$5.0 million in shareholder equity based on Mannin's current valuation of CAD$30 million. The companies anticipate that Mannin's drug pipeline for glaucoma, kidney disease, and ARDS will drive significant future value through clinical milestones and potential strategic partnerships.PR NewswireQ BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar MarketsQ BioMed Inc., a commercial-stage biotechnology company, outlined its 2022 strategy and pipeline across four focus areas: commercial product revenue growth, partnerships, joint venture equity value, and future development platform. The company reported Strontium89 revenue growth with a $500,000 order received for the Chinese market, while partner Mannin Research raised over $10 million for ARDS therapeutic development ahead of Phase I trials. Management expressed disappointment with the current market cap, indicating efforts to restructure capital and pursue a Nasdaq uplisting, with the Mannin equity stake potentially valued at approximately $60 million.PR NewswireMannin GmbH Implements CDD Vault Informatics Platform to Facilitate Data Management and CollaborationMannin GmbH, a German biotech company developing vascular therapeutics including treatments for glaucoma, has implemented CDD Vault, a hosted research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), to manage its research data and enable collaboration across its geographically distributed operations including labs in Leipzig and a parent company in Toronto. The platform will support Mannin's drug discovery pipeline spanning small molecules and biologics targeting conditions such as Primary Open Angle Glaucoma, Cystic Kidney Disease, and pediatric glaucoma.PR NewswireQ BioMed Updates Shareholders at Year EndQ BioMed Inc. issued a year-end shareholder letter outlining its 2021 pipeline milestones, including expected Medicare reimbursement and federal supplier approval for its Strontium89 bone cancer treatment in January 2021, enabling sales to VA and DoD hospital systems. The company is advancing MAN-19, a COVID-19 therapeutic for Acute Respiratory Distress Syndrome, in partnership with Mannin Research Inc., with an IND application planned for Q1 2021, and is also developing glaucoma treatments with McMaster University and a liver cancer drug with Chemveda Life Sciences. Q BioMed has begun the process to uplist from OTCQB to NASDAQ as part of its strategic goals.NewswireQ BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 ConsortiumMannin Research Inc. joined the Canadian national COVID Cloud consortium, developing a software platform for genomics and health data to support COVID-19 research. The consortium will expand development with $5.1M CAD in co-funding from Canada's Digital Technology Supercluster. Mannin Research is developing a host-directed therapeutic for COVID-19 patients with Acute Respiratory Distress Syndrome.PR NewswireQ BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 ConsortiumQ BioMed announced that its technology partner Mannin Research Inc. has joined Canada's national COVID Cloud consortium, a collaboration developing a software platform for genomics and health data to advance COVID-19 research and drug development. The consortium is co-funded with $5.1 million CAD by Canada's Digital Technology Supercluster and includes partners such as BioSymetrics, McGill University, DNAstack, Microsoft Canada, Roche Canada, and other research institutions. Mannin Research will use the platform to support development of its novel therapeutic candidate MAN-19, a host-directed treatment for COVID-19 patients suffering from Acute Respiratory Distress Syndrome.PR NewswireQ BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial ProgramQ BioMed Inc. announced the initiation of GMP production for MAN-19, a novel therapeutic targeting COVID-19 complications, developed with technology partner Mannin Research. Phase 1 clinical trials are scheduled to begin patient enrollment in February 2021. The accelerated development is being partially funded by the Canadian and German governments under COVID-19 response initiatives, with the therapeutic designed to stabilize vascular endothelium and prevent acute respiratory distress syndrome in severely ill patients.PR NewswireHuman Trials Forge Ahead For Development of COVID-19 Vaccine For Global ImmunizationQ BioMed announced a joint venture with Mannin Research and Cyclica to accelerate the development of novel therapeutics targeting vascular leakage caused by viral infections like COVID-19. Concurrently, Inovio Pharmaceuticals secured $6.9 million in funding from CEPI for Phase 1/2 clinical trials of its COVID-19 vaccine candidate in South Korea. Other major biotech firms including Novartis and Gilead Sciences are also advancing their respective contributions to the global pandemic response through drug donations and compassionate use data analysis.PR NewswireQ BioMed Initiates Rapid Development of Novel COVID-19 TherapeuticsQ BioMed Inc. announced on April 22, 2020, that it is accelerating the development of novel COVID-19 therapeutics together with technology partner Mannin Research through a joint venture with Cyclica, a Toronto-based biotechnology company, to deploy Cyclica's AI-augmented drug discovery platform.